CRTC-CREB Axis as a Sensor of Proteotoxic Stress via Proteasome Inhibition

Study Background and Research Question

Proteostasis, or the maintenance of protein homeostasis, is fundamental for cellular function and organismal health. Disruption of proteostasis by proteasome inhibition leads to protein misfolding and aggregation, events central to both neurodegenerative and oncological diseases. The cAMP Response Element Binding Protein (CREB) is a transcription factor known to respond to diverse signaling cues, including those that regulate cell growth, synaptic plasticity, and metabolism. The reference study (Yin et al., 2022) investigates how the CREB pathway, particularly its coactivator CRTC, responds to proteotoxic stress induced by proteasome inhibition in Drosophila, aiming to elucidate the molecular sensors and effectors that underlie this adaptive transcriptional response.

Key Innovation from the Reference Study

The central innovation of this work lies in the identification of the CRTC-CREB axis as a rapid, ROS/JNK-dependent transcriptional sensor activated by proteasome inhibitors such as MLN2238. While CREB's role as a nodal transcription factor is well-established, its direct responsiveness to proteotoxic stress via upstream redox signals had not been fully elucidated in vivo. Notably, the study demonstrates that not only does proteasome inhibition robustly increase CREB activity in adult flies, but that this response is mediated by reactive oxygen species (ROS) through the c-Jun N-terminal kinase (JNK) pathway, thus linking proteasome function, redox biology, and transcriptional adaptation.

Methods and Experimental Design Insights

The authors employed a combination of genetic, pharmacological, and transcriptomic approaches in Drosophila and mammalian cell models. Key methodological features include:

• High-throughput compound screening in adult flies using the U-GLAD (U shape Gum Arabic Liquid Assisted Drug delivery) system to ensure efficient and reproducible delivery of poorly soluble proteasome inhibitors, including MLN2238.
• Genetic manipulation of CRTC and CREB activity in specific tissues (e.g., muscle, intestine) using targeted overexpression and mutant analysis to dissect functional consequences under stress conditions.
• Measurement of CREB transcriptional activity via reporter assays and quantification of phosphorylation events (e.g., Ser133 in 293T cells) to establish signaling dependencies.
• Transcriptome profiling to identify downstream gene expression changes upon CRTC overexpression and proteasome inhibitor treatment, focusing on redox and proteostatic pathways.
• Assessment of proteostasis restoration and disease phenotypes in a fly Huntington’s disease (HD) model to evaluate functional relevance.

This multifaceted design allowed for mechanistic dissection of the signaling cascade from proteasome inhibition to transcriptional adaptation, as well as evaluation of its physiological and pathophysiological consequences.

Core Findings and Why They Matter

• Proteasome inhibitors directly activate CREB in vivo: Using the U-GLAD system, the study found that all FDA-approved proteasome inhibitors tested—including MLN2238—lead to robust activation of CREB in adult flies (Yin et al., 2022).
• ROS and JNK signaling are essential mediators: Proteasome inhibition induces ROS production, which is necessary and sufficient for CREB activation. JNK acts downstream of ROS and is required for CREB phosphorylation (Ser133 in mammalian cells), establishing a conserved redox-stress signaling axis.
• CRTC overexpression augments proteostasis and stress resistance: Enhancing CRTC activity in muscle or intestine leads to upregulation of genes implicated in redox balance and protein homeostasis. In a Drosophila HD model, CRTC overexpression restored proteasomal activity, reduced protein aggregation, improved motility, and extended lifespan.
• Age-related upregulation of CREB activity: The study observes that CREB activity naturally increases with aging, and further enhancement can suppress protein aggregation in aged tissues, suggesting a compensatory adaptation to increased proteotoxic burden.
• Translational implications: These findings highlight the CRTC/CREB axis as a potential therapeutic target for diseases hallmarked by proteotoxic and oxidative stress, including neurodegenerative and cancer models where proteasome function is compromised.

Comparison with Existing Internal Articles

Several recent articles contextualize the significance of MLN2238 and the CRTC-CREB axis in oncology and proteostasis research:

• "MLN2238: Precision Proteasome Inhibition for Advanced Hem..." expands on the molecular specificity of MLN2238 as a reversible proteasome β5 subunit inhibitor and its ability to reveal CRTC/CREB-mediated stress responses in hematologic malignancies. The present reference study experimentally validates this mechanistic link in vivo, providing a direct demonstration of CREB activation via proteasome β5 subunit inhibition.
• "MLN2238 as a Proteasome β5 Subunit Inhibitor in Oncology Research" discusses how MLN2238 facilitates dissection of proteasome-mediated stress responses and drug resistance in multiple myeloma and lymphoma. These articles theorized a role for the CRTC-CREB axis, which the reference paper now substantiates with robust genetic and signaling evidence.
• "MLN2238: Mechanistic Insights and CREB Axis Implications in Proteasome Inhibition Research" emphasizes the interplay between proteasome inhibition, CREB signaling, and oxidative stress. The current reference paper provides the in vivo mechanistic underpinnings and experimental validation for these proposed pathways.

Together, the reference study advances prior theoretical and in vitro insights by establishing causality and physiological relevance in an animal model, solidifying the importance of chymotrypsin-like proteasome inhibition in modulating transcriptional and redox responses.

Limitations and Transferability

While the study provides compelling evidence for the role of the CRTC-CREB axis in Drosophila and mammalian cells, several limitations should be considered:

• Model system specificity: Most findings are derived from Drosophila and 293T cell models. While many signaling pathways are evolutionarily conserved, the exact regulatory dynamics and downstream targets in human tissues, especially in oncology contexts, require further validation.
• Dose and compound specificity: The study primarily assessed the effects of proteasome inhibitors at concentrations relevant for model organisms; translation to human cell lines and tissues may necessitate dose optimization and pharmacokinetic considerations.
• Long-term outcomes: The chronic consequences of sustained CREB activation, redox imbalance, or proteasome inhibition in more complex mammalian systems remain to be investigated, particularly regarding potential adverse effects in cancer or neurodegeneration.
• Clinical translation: While the CRTC/CREB axis emerges as a promising target, therapeutic modulation in humans must account for possible off-target effects and tissue-specific responses.

Protocol Parameters

• Proteasome inhibitor delivery: For in vivo Drosophila studies, the U-GLAD system enables effective administration of poorly water-soluble compounds like MLN2238. For cell-based assays, MLN2238 can be dissolved in DMSO or ethanol, with sonication and warming recommended for optimal solubility according to the product information.
• Dose selection: Literature suggests chymotrypsin-like proteasome inhibition is achieved with MLN2238 at low nanomolar concentrations (IC50 for β5: 3.4 nM), but titration for cell type and experimental context is advised.
• Analysis of CREB activity: Employ validated reporter assays or antibody-based detection of CREB phosphorylation (Ser133 or homologous residues) to monitor pathway activation in response to proteasome inhibition.
• Assessment of ROS and JNK involvement: Include ROS scavengers or JNK pathway inhibitors to dissect signaling dependencies, as shown in the reference study.
• Protein aggregation models: For proteinopathy research (e.g., HD models), combine proteasome inhibition with genetic manipulation of CREB/CRTC to evaluate effects on aggregate formation and cellular viability.

Research Support Resources

Researchers investigating proteasome β5 subunit inhibition, chymotrypsin-like proteasome inhibition, or the CRTC-CREB signaling axis in contexts such as multiple myeloma, lymphoma, or protein aggregation disorders may consider MLN2238 (SKU A4008) for in vitro and in vivo studies. The compound’s selectivity profile and reversible inhibition have been characterized in both oncology and fundamental proteostasis research. Detailed handling and solubility protocols are available from APExBIO to support reproducible experimentation.